Home LiteratureArticle Details
PMID: 18063750 Published · ppublish English Journal Article Research Support, N.I.H., Extramural

Escape from suppression: tumor-specific effector cells outcompete regulatory T cells following stem-cell transplantation.

Blood ·Vol. 111 ·No. 4 ·2008-02-15 ·Pages 2112-21

Mirmonsef P, Tan G, Zhou G, Morino T, Noonan K, Borrello I, Levitsky HI

Abstract

Immune reconstitution of autologous hematopoietic stem-cell transplant recipients with the progeny of mature T cells in the graft leads to profound changes in the emerging functional T-cell repertoire. In the steady state, the host is frequently tolerant to tumor antigens, reflecting dominant suppression of naive and effector T cells by regulatory T cells (T(regs)). We examined the relative frequency and function of these 3 components within the tumor-specific T-cell compartment during immune reconstitution. Grafts from tumor-bearing donors exerted a significant antitumor effect in irradiated, syngeneic tumor-bearing recipients. This was associated with dramatic clonal expansion and interferon-gamma (IFNgamma) production by previously tolerant tumor-specific T cells. While donor-derived T(regs) expanded in recipients, they did not inhibit the antigen-driven expansion of effector T cells in the early posttransplantation period. Indeed, the repopulation of tumor-specific effector T cells significantly exceeded that of T(regs), the expansion of which was limited by IL-2 availability. Although the intrinsic suppressive capacity of T(regs) remained intact, their diminished frequency was insufficient to suppress effector cell function. These findings provide an explanation for the reversal of tolerance leading to tumor rejection in transplant recipients and likely contribute to the efficacy of adoptive T-cell therapies in lymphopenic hosts.

MeSH Terms
Adoptive Transfer Animals Hematopoietic Stem Cell Transplantation Immune Tolerance Immunosuppression Therapy Interferon-gamma/immunology Interleukin-2/immunology Lymphocyte Depletion Lymphoma/immunology Mice Mice, Inbred BALB C Receptors, Antigen, T-Cell/immunology T-Lymphocytes, Regulatory/immunology
Chemicals
Interleukin-2 Receptors, Antigen, T-Cell Interferon-gamma
Authors & Affiliations
7 authors, click to expand affiliations / ORCID
Mirmonsef Paria
Department of Oncology, Johns Hopkins School of Medicine, Baltimore, MD 21231, USA.
Tan Gladys
Zhou Gang
Morino Tricia
Noonan Kimberly
Borrello Ivan
Levitsky Hyam I
References (43)
43 references, click to expand
  1. Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines.
    Blood. 2006 Jan 15;107(2):628-36 PMID: 16179369
  2. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells.
    J Exp Med. 2005 Oct 3;202(7):907-12 PMID: 16203864
  3. Control of regulatory T cell development by the transcription factor Foxp3.
    Science. 2003 Feb 14;299(5609):1057-61 PMID: 12522256
  4. Homeostatic proliferation is a barrier to transplantation tolerance.
    Nat Med. 2004 Jan;10(1):87-92 PMID: 14647496
  5. CD40-independent pathways of T cell help for priming of CD8(+) cytotoxic T lymphocytes.
    J Exp Med. 2000 Feb 7;191(3):541-50 PMID: 10662799
  6. Thymic selection of CD8+ single positive cells with a class II major histocompatibility complex-restricted receptor.
    J Exp Med. 1994 Jul 1;180(1):25-34 PMID: 8006585
  7. Homeostasis and anergy of CD4(+)CD25(+) suppressor T cells in vivo.
    Nat Immunol. 2002 Jan;3(1):33-41 PMID: 11740498
  8. Tolerance, not immunity, crucially depends on IL-2.
    Nat Rev Immunol. 2004 Sep;4(9):665-74 PMID: 15343366
  9. Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer.
    Nat Med. 2005 Nov;11(11):1230-7 PMID: 16227990
  10. Normal regulatory alpha/beta T cells effectively eliminate abnormally activated T cells lacking the interleukin 2 receptor beta in vivo.
    J Exp Med. 1999 Dec 6;190(11):1561-72 PMID: 10587347
  11. Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD8 T cells.
    J Clin Invest. 2007 Feb;117(2):492-501 PMID: 17273561
  12. T cell-mediated immunosuppression as an obstacle to adoptive immunotherapy of the P815 mastocytoma and its metastases.
    J Exp Med. 1981 Oct 1;154(4):1033-42 PMID: 6457075
  13. Bone marrow transplantation and approaches to avoid graft-versus-host disease (GVHD).
    Philos Trans R Soc Lond B Biol Sci. 2005 Sep 29;360(1461):1747-67 PMID: 16147539
  14. Sustaining the graft-versus-tumor effect through posttransplant immunization with granulocyte-macrophage colony-stimulating factor (GM-CSF)-producing tumor vaccines.
    Blood. 2000 May 15;95(10):3011-9 PMID: 10807763
  15. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes.
    Science. 2002 Oct 25;298(5594):850-4 PMID: 12242449
  16. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma.
    J Clin Oncol. 2005 Apr 1;23(10):2346-57 PMID: 15800326
  17. An essential role for Scurfin in CD4+CD25+ T regulatory cells.
    Nat Immunol. 2003 Apr;4(4):337-42 PMID: 12612581
  18. In vivo dynamics of antigen-specific regulatory T cells not predicted from behavior in vitro.
    Proc Natl Acad Sci U S A. 2003 Jul 22;100(15):8886-91 PMID: 12857946
  19. CD4+CD25+ T regulatory cells, immunotherapy of cancer, and interleukin-2.
    J Immunother. 2005 Mar-Apr;28(2):120-8 PMID: 15725955
  20. Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease.
    Immunol Rev. 2006 Aug;212:8-27 PMID: 16903903
  21. Lymphopenia and interleukin-2 therapy alter homeostasis of CD4+CD25+ regulatory T cells.
    Nat Med. 2005 Nov;11(11):1238-43 PMID: 16227988
  22. Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy.
    Trends Immunol. 2005 Feb;26(2):111-7 PMID: 15668127
  23. Regulatory CD4 T cells control the size of the peripheral activated/memory CD4 T cell compartment.
    J Immunol. 2000 Apr 1;164(7):3573-80 PMID: 10725712
  24. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self.
    Nat Immunol. 2005 Apr;6(4):345-52 PMID: 15785760
  25. T cell homeostatic proliferation elicits effective antitumor autoimmunity.
    J Clin Invest. 2002 Jul;110(2):185-92 PMID: 12122110
  26. CD25+ CD4+ T cells regulate the expansion of peripheral CD4 T cells through the production of IL-10.
    J Immunol. 2001 Mar 1;166(5):3008-18 PMID: 11207250
  27. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells.
    Nat Immunol. 2003 Apr;4(4):330-6 PMID: 12612578
  28. Induction of antigen-specific T cell anergy: An early event in the course of tumor progression.
    Proc Natl Acad Sci U S A. 1998 Feb 3;95(3):1178-83 PMID: 9448305
  29. Gamma-irradiation facilitates the expression of adoptive immunity against established tumors by eliminating suppressor T cells.
    Cancer Immunol Immunother. 1984;16(3):175-81 PMID: 6231095
  30. Immunosuppressive networks in the tumour environment and their therapeutic relevance.
    Nat Rev Cancer. 2005 Apr;5(4):263-74 PMID: 15776005
  31. Graft-versus-myeloid leukemia responses following syngeneic and allogeneic bone marrow transplantation.
    Transplantation. 1994 Aug 15;58(3):278-87 PMID: 7914387
  32. Interleukin-2 receptor alpha chain regulates the size and content of the peripheral lymphoid compartment.
    Immunity. 1995 Oct;3(4):521-30 PMID: 7584142
  33. Development and function of T cells in mice rendered interleukin-2 deficient by gene targeting.
    Nature. 1991 Aug 15;352(6336):621-4 PMID: 1830926
  34. CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells.
    J Clin Invest. 2006 Jul;116(7):1935-45 PMID: 16778987
  35. Interleukin-2-dependent mechanisms of tolerance and immunity in vivo.
    J Immunol. 2006 May 1;176(9):5255-66 PMID: 16621991
  36. Coexpression of CD25 and CD27 identifies FoxP3+ regulatory T cells in inflamed synovia.
    J Exp Med. 2005 Jun 6;201(11):1793-803 PMID: 15939793
  37. Natural regulatory T cells and de novo-induced regulatory T cells contribute independently to tumor-specific tolerance.
    J Immunol. 2007 Feb 15;178(4):2155-62 PMID: 17277120
  38. Detection of early and delayed antitumor effects following curative adoptive chemoimmunotherapy of established leukemia.
    Cancer Res. 1980 Dec;40(12):4428-32 PMID: 7438073
  39. IL-2 and IL-15 each mediate de novo induction of FOXP3 expression in human tumor antigen-specific CD8 T cells.
    J Immunother. 2007 Apr;30(3):294-302 PMID: 17414320
  40. T-cell-mediated suppression of anti-tumor immunity. An explanation for progressive growth of an immunogenic tumor.
    J Exp Med. 1980 Jan 1;151(1):69-80 PMID: 6444236
  41. Immunization with granulocyte-macrophage colony-stimulating factor-transduced, but not B7-1-transduced, lymphoma cells primes idiotype-specific T cells and generates potent systemic antitumor immunity.
    J Immunol. 1996 May 15;156(10):3858-65 PMID: 8621924
  42. Maintaining the norm: T-cell homeostasis.
    Nat Rev Immunol. 2002 Aug;2(8):547-56 PMID: 12154374
  43. Augmentation of host immune responses to cancer: overcoming the barrier of tumor antigen-specific T-cell tolerance.
    Cancer J. 2000 May;6 Suppl 3:S281-90 PMID: 10874499
Article Info
Journal
Blood
Abbr.
Blood
ISSN
0006-4971
Published
2008-02-15
Epub
2007-00-06
Pages
2112-21
Language
English
Region
United States
NLM ID
7603509
PMCID
PMC2234051
Subset
IM
Grants
NCI NIH HHS · P01 CA015396 · United States
NCI NIH HHS · P01CA15396 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]